Skip to main content
ADCES 2026 Annual Conference Main banner

Cardiometabolic Conditions and Treatment Options

(S04) Doubling Down: SGLT2 Meets Aldosterone in Cardio-Kidney Care

Saturday, August 8, 2026
9:45 AM - 10:30 AM ET
CE: .75 CE
Pharmacology Hours: .50 CE
Cardio-kidney protection in diabetes is entering an exciting new era. Nonsteroidal mineralocorticoid receptor antagonists (MRAs) and sodium-glucose cotransporter 2 (SGLT2) inhibitors have transformed care for chronic kidney disease and heart failure, but can these powerful therapies safely and effectively work together? This session dives into the latest evidence, controversies, and strategies for combination therapy through the lens of precision medicine--delivering the right therapy at the right time for the right person. Looking ahead, the speakers will spotlight emerging agents like aldosterone synthase inhibitors and their potential to further enhance outcomes. Join us for a dynamic discussion blending science, clinical pearls, and future innovations in diabetes-cardio-kidney care.

Learning Objectives:

At the completion of this activity, participants should be able to:
  • Describe the mechanisms and clinical benefits of aldosterone antagonists and SGLT2 inhibitors in diabetes-related chronic kidney disease and heart failure.
  • Evaluate evidence and controversies surrounding concurrent use of aldosterone antagonists and SGLT2 inhibitors, including potential synergistic effects and safety concerns.
  • Explore emerging therapies and integrate strategies including precision medicine, monitoring, and risk mitigation in using aldosterone antagonists and SGLT2 inhibitors.
Disclosure(s):
Jennifer Rosselli, PharmD, BCACP, BC-ADM, CDCES: Medtronic, Inc.: Consultant / Advisory Board (Terminated, February 28, 2025)
Sydnie E. Twillmann, PharmD, BCACP: No financial relationships to disclose